Join Endpoints News and key industry leaders as we recap the major conversations out of ASCO and look ahead towards oncology pipelines over the next year. We’re taking a close look at new readouts, lo...

Fred Ramsdell, who won the Nobel Prize in Physiology or Medicine with Mary Brunkow and Shimon Sakaguchi, spoke with Endpoints on Monday about the 'surreal' honor, cell therapy for autoimmune diseases,...

Biopharma companies spent $4B+ in 2025 on in vivo CAR-T startups, including BMS's $1.5B Orbital deal, as first human data emerges from China via Esobiotec's multiple myeloma trial.

Patients, researchers and advocates are imploring J&J to apply for approval of the X-linked retinitis pigmentosa gene therapy known as bota-vec despite a failed Phase 3 study

Verve Therapeutics is trying to swerve the gene editing industry downturn with new results on a potential one-time treatment to lower cholesterol. The experimental gene editing therapy cut bad cholest...

The industry can’t continue to sit idly by while Robert F. Kennedy Jr. guts the nation’s public health agencies.

Mass firings and forced resignations swept through the FDA on Tuesday, as part of thousands of planned job cuts at federal health agencies being implemented by the Trump administration.

Black Diamond Therapeutics has found a buyer for an early-stage targeted cancer drug, which was brushed to the side last year as it focused resources on developing a next-generation lung ...

A teenage boy who received Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys died from liver failure, the biotech said Tuesday morning.

HHS Secretary Robert F. Kennedy Jr. and his staff last Wednesday hosted a regenerative medicine roundtable primarily to discuss how to lower regulatory barriers for stem cell treatments, three people ...

Two days after announcing plans to shut down an FDA lab devoted to ensuring the US drug supply remains safe and potent, the Trump administration has changed plans and will leave the lab open, Endpoint...

DOGE says that it has terminated the leases of 30 FDA offices and buildings, including a 52,000 square-foot St. Louis-based lab that operates under the FDA's Office of Pharmaceutical Quality.

HHS Secretary Robert F. Kennedy Jr. moved to rescind the longtime practice of giving the public a chance to comment on the health agency’s plans.

Regeneron is now expecting an accelerated approval decision this summer on its T cell engager for one form of lymphoma, while it's giving up on accelerated approval for a different form of the disease...

“Exceptional” fossil collections housed by the Paleontological Research Institute risk being orphaned